Baxalta (now part of Shire)
Clinical trials sponsored by Baxalta (now part of Shire), explained in plain language.
Baxalta was a biopharmaceutical company acquired by Shire, which is now part of Takeda.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New hope for kids with rare bleeding disease: study tests rVWF therapy
Disease control CompletedThis study tested a medicine called vonicog alfa (rVWF), sometimes given with another drug (ADVATE), to control bleeding in 47 children under 18 with severe von Willebrand disease. The treatment was given for 12-18 months, and doctors checked how well it stopped bleeding and if i…
Phase 3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New enzyme therapy shows promise in controlling rare blood clotting disorder
Disease control CompletedThis study tested a medicine called BAX 930 in 52 people born with severe TTP, a rare condition that causes dangerous blood clots. The medicine replaces a missing enzyme to prevent or treat sudden flare-ups. Participants received either BAX 930 or standard treatment for 6 months,…
Phase 3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
One-Time gene therapy shot aims to ease severe hemophilia a
Disease control CompletedThis early-phase trial tested a gene therapy called BAX 888 in 4 men with severe hemophilia A. The therapy uses a harmless virus to deliver a working gene for factor VIII, a blood-clotting protein they lack. Participants received a single intravenous infusion, and the study focus…
Phase 1/2 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 26, 2026 16:52 UTC
-
New hope for rare bleeding disorder: Long-Term drug shows promise
Disease control CompletedThis study tested a drug called rVWF (Vonvendi) in 38 children and adults with severe von Willebrand disease, a bleeding disorder. The goal was to see if regular use of the drug could reduce the number of spontaneous bleeding episodes over a year. Participants received treatment …
Phase 3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 26, 2026 12:56 UTC